WO2001087371A2 - Self-supporting laminated films, structural materials and medical devices - Google Patents
Self-supporting laminated films, structural materials and medical devices Download PDFInfo
- Publication number
- WO2001087371A2 WO2001087371A2 PCT/US2001/015284 US0115284W WO0187371A2 WO 2001087371 A2 WO2001087371 A2 WO 2001087371A2 US 0115284 W US0115284 W US 0115284W WO 0187371 A2 WO0187371 A2 WO 0187371A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stent
- graft
- implantable medical
- medical device
- regions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
- A61L27/047—Other specific metals or alloys not covered by A61L27/042 - A61L27/045 or A61L27/06
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
- A61L27/06—Titanium or titanium alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
Definitions
- the present invention pertains generally to implantable medical devices and, more particularly, to implantable medical devices fabricated of self-supporting laminated films fashioned into geometric configurations adapted to specific medical uses. More particularly, the present invention relates to metal films, foils, wires and seamless tubes, with increased mechanical properties, which are suitable for use in fabricating implantable endoluminal grafts, stent-grafts and stent-graft-type devices.
- the present invention comprises endoluminal grafts, stent-grafts and stent-graft-type devices that are fabricated entirely of self-supporting laminated films, foils, wires or seamless tubes made of biocompatible metals or of biocompatible materials which exhibit biological response and material characteristics substantially the same as biocompatible metals, such as for example composite materials.
- inventive materials are made of at least two layers formed upon one another into a self- supporting laminate structure.
- Laminate structures are generally known to increase the mechanical strength of sheet materials, such as wood or paper products. Laminates are used in the field of thin film fabrication also to increase the mechanical properties of the thin film, specifically hardness and toughness.
- Laminate metal foils have not been used or developed because the standard metal forming technologies, such as rolling and extrusion, for example, do not readily lend themselves to producing laminate structures. Vacuum deposition technologies can be developed to yield laminate metal structures with improved mechanical properties. In addition, laminate structures can be designed to provide special qualities by including layers that have special properties such as superelasticity, shape memory, radio- opacity, corrosion resistance etc.
- Metal foils, wires and thin-walled seamless tubes are typically produced from ingots in a series of hot or cold forming steps that include some combination of rolling, pulling, extrusion and other similar processes. Each of these processing steps is accompanied by auxiliary steps that include cleaning the surfaces of the material of foreign material residues deposited on the material by the tooling and lubricants used in the metal forming processes. Additionally, chemical interaction with tooling and lubricant materials and ambient gases also introduces contaminants. Some residue will still usually remain on the surface of the formed material, and there is a high probability that these contaminating residues become incorporated during subsequent processing steps into the bulk of the wrought metal product. With decreasing material product size, the significance of such contaminating impurities increases.
- the forming and shaping processes used to fabricate metal foils, wires and thin-walled seamless tubes involves heavy deformation of a bulk material, which results in a heavily strained and deformed grain structure. Even though annealing treatments may partially alleviate the grain deformation, it is typically impossible to revert to well-rounded grain structure and a large range of grain sizes is a common result.
- the end result of conventional forming and shaping processes, coupled with annealing, typically results in non-uniform grain structure and less favorable mechanical properties in smaller sized wrought metal products. It is possible, therefore, to produce high quality homogeneous materials for special purposes, such as micromechanical devices and medical devices, using vacuum deposition technologies.
- vacuum deposition technologies materials are formed directly in the desired geometry, e.g., planar, tubular, etc.
- the common principle of the vacuum deposition processes is to take a material in a minimally processed form, such as pellets or thick foils (the source material) and atomize them. Atomization may be carried out using heat, as is the case in physical vapor deposition, or using the effect of collisional processes, as in the case of sputter deposition, for example.
- a process such as laser ablation, which creates microparticles that typically consist of one or more atoms, may replace atomization; the number of atoms per particle may be in the thousands or more.
- the atoms or particles of the source material are then deposited on a substrate or mandrel to directly form the desired object.
- chemical reactions between ambient gas introduced into the vacuum chamber, i.e., the gas source, and the deposited atoms and/or particles are part of the deposition process.
- the deposited material includes compound species that are formed due to the reaction of the solid source and the gas source, such as in the case of chemical vapor deposition. In most cases, the deposited material is then either partially or completely removed from the substrate, to form the desired product.
- the rate of film growth is a significant parameter of vacuum deposition processes.
- deposition rates in excess of 1 micrometers/hour are a must and indeed rates as high as 100 micrometers per hour are desirable. These are high deposition rates and it is known that at such rates the deposits always have a columnar structure.
- the columns may be amorphous or crystalline but at such high deposition rates microcrystalline structure development can be expected at best.
- the difficulty is that the columns provide a mechanically weak structure in which crack propagation can occur uninhibited across the whole thickness of the deposit.
- a special advantage of vacuum deposition technologies is that it is possible to deposit layered materials and thus films possessing exceptional qualities may be produced (c.f., H. Holleck, V. Schier: "Multilayer PVD coatings for wear protection", Surface and Coatings Technology, Vol. 76-77 (1995) pp. 328-336).
- Layered materials such as superstructures or multilayers, are commonly deposited to take advantage of some chemical, electronic, or optical property of the material as a coating; a common example is an antireflective coating on an optical lens. It has not been recognized until relatively recently that multilayer coatings may have improved mechanical properties compared with similar coatings made of a single layer. The improved mechanical properties may be due to the ability of the interface between the layers to relieve stress.
- the inventive process consists of the steps of providing a substrate, depositing a first layer of material on the substrate, depositing a second layer of material on the first layer of material and optionally removing the layered material from the substrate.
- the last step is necessary in the case of making foils and seamless tubes but would be omitted in the case of making wires.
- the substrate itself is a thin wire that becomes part of the final product.
- the number of layers is more than two. There is no limitation regarding the number of layers and regarding the thickness of each layer.
- a "layer” is intended to mean a substantially uniform material limited by interfaces between it and adjacent other substantially homogeneous layers, substrate, or environment.
- the interface region between adjacent layers is an inhomogeneous region in which extensive thermodynamic parameters may change.
- Different layers are not necessarily characterized by different values of the extensive thermodynamic parameters but at the interface, there is a local change at least in some parameters.
- the interface between two steel layers that are identical in composition and microstructure may be characterized by a high local concentration of grain boundaries due to an interruption of the film growth process.
- the interface between layers is not necessarily different in chemical composition if it is different in structure.
- the width of the interface region may be defined as the range within which extensive thermodynamic parameters change. This range can depend on the interface area considered and it may mean the extent of interface microroughness. In other words, adhesion may be promoted by increased interface microroughness between adjacent layers.
- the inventive materials consist of a controlled maximum size of grains and columns as extended defects in the direction of the film growth (perpendicular to the layers). This limit of the grain or defect size results in materials that have increased mechanical strength and particularly increased toughness compared to their non-laminated counterparts, both deposited and wrought materials. In addition, limiting the extent to which defects and grain boundaries reach across the laminate, corrosion resistance is also improved.
- Laminated materials will have additional advantages when chemical compositions of the layers are chosen to achieve special properties.
- a radiopaque material such as Ta may form one layer of a structure while other layers are chosen to provide the material with necessary mechanical and other properties.
- metal-like materials an implantable graft fabricated of laminated films of biocompatible metals or biocompatible materials which exhibit in vivo biological and mechanical responses substantially the same as biocompatible metals (hereinafter referred to as "metal-like materials"); 2) an implantable stent-graft device in which a structural component, or stent, and a graft component are each fabricated of laminated films of metal or metal-like materials; 3) an implantable stent-graft-type device in which a structural support, such as a stent, defines openings which are subtended by a web, with both the stent and the web being formed as a single
- a graft member is formed as a discrete thin sheet or tube of biocompatible metals or metal-like material.
- a plurality of openings is provided which pass transversely through the graft member.
- the plurality of openings may be random or may be patterned. It is preferable that the size of each of the plurality of openings be such as to permit cellular migration through each opening, without permitting fluid flow there through.
- first and second graft members have a pattern of a plurality of openings passing there through.
- the first and second graft members are positioned concentrically with respect to one another, with the plurality of patterned openings being positioned out of phase relative to one another such as to create a tortuous cellular migration pathway through the wall of the concentrically engaged first and second graft members.
- These additional cellular migration pathways may be imparted as 1) a plurality of projections formed on either the luminal surface of the second graft or the abluminal surface of the first graft, or both, which serve as spacers and act to maintain an annular opening between the first and second graft members that permits cellular migration and cellular communication between the plurality of openings in the first and second graft members, or 2) a plurality of microgrooves, which may be random, radial, helical, or longitudinal relative to the longitudinal axis of the first and second graft members, the plurality of microgrooves being of a sufficient size to permit cellular migration and propagation along the groove without permitting fluid flow there through, the microgrooves serve as cellular migration conduits between the plurality of openings in the first and second graft members.
- a graft member may be formed as either a thin sheet of material or as a tubular member, and mechanically joined to cover a plurality of structural support members.
- the graft member may be used to cover either a luminal or abluminal surface, or both, of an endoluminal device.
- a stent-graft in accordance with the present invention may be formed by conjoining a discrete graft member with a plurality of structural support members, such as a stent, by mechanically joining the graft member to regions of the plurality of structural support members.
- a stent-graft may be formed by first forming, such as by vacuum deposition methods or by etching a pre-existing material blank, a graft member as a contiguous thin sheet or tube which projects outwardly from at least one aspect of the plurality of structural members.
- the thin sheet is then everted over the structural members and brought into a position adjacent a terminal portion of the plurality of structural members such that it covers one or both of the putative luminal or abluminal surfaces of the plurality of structural members.
- the graft member is then mechanically joined at an opposing end, i.e., the putative proximal or the putative distal end of the plurality of structural members.
- the stent-graft is formed entirely of a metal or metal-like material, which, as opposed to using conventional synthetic polymeric graft materials, the inventive graft material exhibits improved healing response.
- a stent-graft-type device termed a "web-stent” in which there is at least one of a plurality of structural members that provide a primary means of structural support for the webbed-stent device.
- the plurality of structural members may be arranged in any manner as is known in the art of stent fabrication, e.g., single element forming a circle or ellipse, a single or plural elements which form a tubular diamond-like or undulating pattern, in which adjacent structural members are spaced apart forming open regions or interstices between adjacent structural members.
- the interstices or open regions between adjacent structural members are subtended by a web of material that is the same material or a material exhibiting similar biological and mechanical response as the material that forms the plurality of structural members.
- the web may be formed within all or a portion of the interstitial area or open regions between the plurality of structural support members.
- the present invention provides a method of fabricating the graft, stent-graft and web-stent devices of the present invention.
- the inventive method consists of forming the device by vacuum deposition of a film, either as a planar sheet or as a tube, of a biocompatible material, such as nickel-titanium alloys. The thickness of the deposited material is determined by the particular embodiment being fabricated. After the deposited film is created, either additive or subtractive methodologies are employed to define: the structural members, the interstitial web regions, the graft regions and/or a plurality of openings through the deposited film.
- a pre-fabricated starting film of a biocompatible material such as Nitinol
- the thickness of the deposited or prefabricated starting film may be less than that where a web-stent is being formed, due to the absence of structural members in the graft member.
- structural members may be formed by alternative methods.
- the structural members may be formed by additive techniques by applying a pattern of structural members onto a film, such as by vacuum deposition techniques or conventional metal forming techniques, such as laminating or casting. Second, subtractive or selective removal techniques may be employed to remove material from patterned regions on a film, such as by etching a pattern of interstitial regions between adjacent structural members until a thinner film is created which forms the web subtending the plurality of structural members. Where a pre-existing stent is employed as the structural members, obviously, the structural members do not need to be fabricated or formed.
- the graft, the plurality of structural members and the web are fabricated of the same or similar metals or metal-like materials.
- the materials employed have substantially homogenous surface profiles at the blood or tissue contact surfaces thereof.
- a substantially homogeneous surface profile is achieved by controlling heterogeneities along the blood or tissue-contacting surface of the material.
- the heterogeneities that are conuOlled in accordance with an embodiment of the present invention include: grain size, grain phase, grain material composition, stent-material composition, and surface topography at the blood flow surface of the stent.
- the present invention provides methods of making endoluminal devices having controlled heterogeneities in the device material along the blood flow or tissue-contacting surface of the device.
- Material heterogeneities are preferably controlled by using conventional methods of vacuum deposition of materials onto a substrate.
- the surface of a solid, homogeneous material can be conceptualized as having unsaturated inter-atomic and intermolecular bonds forming a reactive plane ready to interact with the environment.
- a perfectly clean surface is unattainable because of immediate adsorption of airborne species, upon exposure to ambient air, of O, 0 2 , CO , SO , NO, hydrocarbons and other more complex reactive molecules.
- Reaction with oxygen implies the formation of oxides on a metal surface, a self-limiting process, known as passivation.
- An oxidized surface is also reactive with air, by adsorbing simple, organic airborne compounds. Assuming the existence of bulk material of homogeneous subsurface and surface composition, oxygen and hydrocarbons may adsorb homogeneously. Therefore, further exposure to another environment, such as the vascular compartment, may be followed by a uniform biological response.
- stents are made from bulk metals made by conventional methods which employ many steps that introduce processing aides to the metals make stent precursors, such as hypotubes.
- stent precursors such as hypotubes.
- olefins trapped by cold drawing and transformed into carbides or elemental carbon deposit by heat treatment typically yield large carbon rich areas in 316L stainless steel tubing manufactured by cold drawing process.
- the conventional stents have marked surface and subsurface heterogeneity resulting from manufacturing processes (friction material transfer from tooling, inclusion of lubricants, chemical segregation from heat treatments). This results in formation of surface and subsurface inclusions with chemical composition and, therefore, reactivity different from the bulk material.
- Oxidation, organic contamination, water and electrolytic interaction, protein adsorption and cellular interaction may, therefore, be altered on the surface of such inclusion spots.
- Unpredictable distributions of inclusions such as those mentioned above provide unpredictable and uncontrolled heterogeneous surface available for interaction with plasma proteins and cells. Specifically, these inclusions interrupt the regular distribution pattern of surface free energy and electrostatic charges on the metal surface that determine the nature and extent of plasma protein interaction.
- Plasma proteins deposit nonspecifically on surfaces according to their relative affinity for polar or non-polar areas and their concentration in blood. A replacement process known as the Vroman effect, Vroman L., The importance of surfaces in contact phase reactions.
- endothelial cells migrate and proliferate to cover denuded areas until confluence is achieved. Migration, quantitatively more important than proliferation, proceeds under normal blood flow roughly at a rate of 25 ⁇ m/hr or 2.5 times the diameter of an EC, which is nominally lO ⁇ m.
- EC migrate by a rolling motion of the cell membrane, coordinated by a complex system of intracellular filaments attached to clusters of cell membrane integrin receptors, specifically focal contact points. The integrins within the focal contact sites are expressed according to complex signaling mechanisms and eventually couple to specific amino acid sequences in substrate adhesion molecules (such as GD, mentioned above).
- An EC has roughly 16-22% of its cell surface represented by integrin clusters. Davies, P.F., Robotewskyi A., Griem M.L. Endothelial cell adhesion in real time. J. Clin. Invest. 1993;
- Irregular or unpredictable distribution of attachment sites that might occur as a result of various inclusions, with spacing equal or smaller to one whole cell length, is likely to determine alternating hostile and favorable attachment conditions along the path of a migrating cell. These conditions may vary from optimal attachment force and migration speed to insufficient holding strength to sustain attachment, resulting in cell slough under arterial flow conditions. Due to present manufacturing processes, current implantable vascular devices exhibit such variability in surface composition as determined by surface sensitive techniques such as atomic force microscopy, X-ray photoelectron spectroscopy and time-of-flight secondary ion mass spectroscopy.
- the underlying stent substrate is characterized by uncontrolled heterogeneities on the surface thereof.
- coatings merely are laid upon the heterogeneous stent surface, and inherently conform to the topographical heterogeneities in the stent surface and mirror these heterogeneities at the blood contact surface of the resulting coating.
- This is conceptually similar to adding a coat of fresh paint over an old coating of blistered paint; the fresh coating will conform to the blistering and eventually, blister and delaminate from the underlying substrate.
- topographical heterogeneities are typically telegraphed through a surface coating.
- Chemical heterogeneities may not be telegraphed through a surface coating but may be exposed due to cracking or peeling of the adherent layer, depending upon the particular chemical heterogeneity.
- the current invention entails creating materials specifically designed for manufacture of grafts, stents, stent-grafts and other endoluminal devices.
- the manufacture of grafts, stents, stent-grafts and other endoluminal devices is controlled to attain a regular, homogeneous atomic and molecular pattern of distribution along their surface. This avoids the marked variations in surface composition, creating predictable oxidation and organic adsorption patterns and has predictable interactions with water, electrolytes, proteins and cells.
- EC migration is supported by a homogeneous distribution of binding domains that serve as natural or implanted cell attachment sites, in order to promote unimpeded migration and attachment.
- binding domains should have a repeating pattern along the blood contact surface of no less than 1 ⁇ m radius and 2 ⁇ m border-to-border spacing between binding domains.
- the inter-binding domain spacing is less than the nominal diameter of an endothelial cell in order to ensure that at any given time, a portion of an endothelial cell is in proximity to a binding domain.
- a laminated film structure and a method of making laminated film structures comprised of at least two of a plurality of plied layers of biocompatible metals or biocompatible materials which exhibits mechanical properties superior to those of a monolithic film structure of substantially equal thickness as the laminated film structure.
- a web-stent device fabricated of a laminated film, in which there is at least one of a plurality of structural members that provides a primary means of structural support for the web-stent device.
- the plurality of structural members is spaced apart to form open regions or interstices between adjacent structural members.
- a web of material that is the same or similar to the material which forms the plurality of structural members, subtends the interstices or open regions between adjacent structural members.
- the web may be formed within all or a portion of the interstitial area or open regions between the plurality of structural support members.
- Both the plurality of interconnected structural members and the web may be formed of initially substantially planar materials or of initially substantially cylindrical materials.
- a stent-graft device in which a graft member is formed as a laminated film of material and mechanically joined to one or both of the proximal and distal ends of the plurality of structural support members, and covers that surface of the plurality of structural support members which is to form either the luminal or abluminal surface of the stent-graft device.
- the graft member may be formed either separately or as a contiguous thin-film projecting from the plurality of structural members.
- the thin film is either abluminally everted or luminally inverted and brought into a position adjacent to the plurality of structural members such that it covers either, or both, the luminal or abluminal surfaces or the plurality of structural members, then is attached at an opposing end, i.e., the putative proximal or the putative distal end of the plurality of structural members.
- a graft formed as a discrete laminated thin sheet or tube of biocompatible metal or metal-like materials.
- a plurality of openings is provided which pass transversely through the graft member.
- the plurality of openings may be random or may be patterned. It is preferable that the size of each of the plurality of openings be such as to permit cellular migration through each opening, without permitting fluid flow there through. In this manner, blood cannot flow through the plurality of openings, but various cells or proteins may freely pass through the plurality of openings to promote graft healing in vivo.
- two graft members are employed, one or both of the graft members being formed of laminated films.
- An outer diameter of a first graft member is dimensioned smaller than the an inner diameter of a second graft member, such that the first graft member is concentrically engageable within a lumen of the second graft member.
- Both the first and second graft members have a plurality of patterned openings passing there through.
- the first and second graft members are positioned concentrically with respect to one another, with the plurality of patterned openings being positioned out of phase relative to one another such as to create a tortuous cellular migration pathway through the wall of the concentrically engaged first and second graft members.
- additional cellular migration pathways that communicate between the plurality of openings in the first and second graft members.
- These additional cellular migration pathways may be imparted as 1) a plurality of projections formed on either the luminal surface of the second graft or the abluminal surface of the first graft, or both, which serve as spacers and act to maintain an annular opening between the first and second graft members and permit cellular migration in order to communicate between the plurality of openings in the first and second graft members, or 2) a plurality of microgrooves, which may be random, radial, helical, or longitudinal relative to the longitudinal axis of the first and second graft members, the plurality of microgrooves being of a sufficient size to permit cellular migration, and propagation along the groove without permitting fluid flow there through, the microgrooves serve as cellular migration conduits between the plurality of openings in the first and second graft members
- the present invention also provides a method of fabricating the web-stent device which entails providing a planar or tubular laminated film of a biocompatible material, such as forming the film by vacuum deposition, then removing interstitial regions until a thinner film region is created which forms a web subtending a plurality of structural members.
- a pre-existing conventionally produced sheet or tube of a biocompatible material such as Nitinol, may be etched until a thinner film is created in the etched regions, thereby forming the interstitial web areas of the web-stent device.
- an implantable endoluminal device that is fabricated from laminated film materials that present a blood or tissue contact surface that is substantially homogeneous in material constitution. More particularly, the present invention provides an endoluminal graft, stent, stent-graft and web- stent that is made of a material having controlled heterogeneities along the blood flow or tissue-contacting surface of the stent.
- Figure 1A is a perspective, partial cross-sectional view of a laminated film sheet structure in accordance with the present invention.
- Figure IB is a perspective, partial cross-sectional view of a laminated film tubular structure in accordance with the present invention.
- Figure 2 is a perspective view of a preferred embodiment of the web-stent of the present invention.
- Figure 3 is a perspective view of a stent-graft in accordance with the present invention.
- Figure 4 is a perspective view of an alternative embodiment of the inventive stent- graft.
- Figure 5 is a cross-sectional view taken along line 5-5 of Figure 4.
- Figure 6 is a cross-sectional view illustrating a pair of support members and a section of interstitial web between adjacent supporting members.
- Figure 7 is a cross-sectional view illustrating a pair of support members and a section of interstitial web between adjacent supporting members in accordance with an alternative embodiment of the present invention.
- Figure 8 A is a top plan view of a graft or web region with a plurality of openings passing there through.
- Figure 8B is a top plan view of an alternative embodiment of a graft or web region of the present invention with a plurality of openings passing there through.
- Figure 8C is a top plan view of a third embodiment of a graft or web region of the present invention with a plurality of openings passing there through.
- Figure 9 A is a transverse cross-sectional view of a first embodiment of a graft member in accordance with the present invention.
- Figure 9B is a transverse cross-sectional view of a second embodiment of a graft member in accordance with the present invention.
- Figure 10 is a flow chart diagrammatically illustrating the method of fabricating the laminated film graft, stent-graft and/or web-stent of the present invention.
- stent, web-stent and stent-graft devices which preferably exhibit substantially homogenous surface properties.
- inventive graft, stent, stent-graft and web-stent devices may be depositing at least two layers of a biocompatible material to form a plied film, either in a planar or cylindrical conformation, then either adding a pattern of support members to the film or removing at least some regions of the plied film to create thinner regions in the starting film and defining relatively thinner and thicker film regions, such as thinner web regions between adjacent structural members formed by thicker film regions and/or relatively thinner graft regions.
- An additive methodology may include vacuum deposition or lamination of a pattern of support members upon the planar or cylindrical film.
- a subtractive methodology includes etching unwanted regions of material by masking regions to form the structural members and expose unmasked regions to the etchant. Additionally, in order to improve in vivo healing, it is advantageous to impart openings passing through the web or the graft.
- the openings are preferably produced during the process of forming the web or the graft.
- the openings in the web or the graft may be formed by conventional methods such as photolithographic processes, by masking and etching techniques, by mechanical means, such as laser ablation, EDM, or micromachining, etc.
- Suitable deposition methodologies as are known in the microelectronic and vacuum coating fabrication arts and incorporated herein by reference, are plasma deposition and physical vapor deposition which are utilized to impart a metal layer onto the stent pattern.
- a vacuum deposited device that is fabricated of a material having substantially homogeneous surface properties across the blood contact surface of the device.
- Current manufacturing methods for fabricating endoluminal stents fail to achieve the desired material properties of the present invention.
- stents are fabricated from bulk metals that are processed in a manner that incorporates processing aides to the base metal.
- stents are made from hypotubes formed from bulk metals, by machining a series of slots or patterns into the hyptotube to accommodate radial expansion, or by weaving wires into a mesh pattern.
- the present invention consists of a stent made of a bulk material having controlled heterogeneities on the luminal surface thereof. Heterogeneities are controlled by fabricating the bulk material of the stent to have defined grain sizes that yield areas or sites along the surface of the stent having optimal protein binding capability.
- the characteristically desirable properties of the inventive stent are: (a) optimum mechanical properties consistent with or exceeding regulatory approval criteria, (b) controlling discontinuities, such as cracking or pinholes, (c) a fatigue life of 400 MM cycles as measured by simulated accelerated testing, (d) corrosion resistance, (e) biocompatibility without having biologically significant impurities in the material, (f) a substantially non-frictional abluminal surface to facilitate atraumatic vascular crossing and tracking and compatible with transcatheter techniques for stent introduction, (g) radiopaque at selected sites and MRI compatible, (h) have a luminal surface which is optimized for surface energy and microtopography, (i) minimal manufacturing and material cost consistent with achieving the desired material properties, and (j) high process yields.
- Controlling the surface profile of an endoluminal device is significant because blood protein interactions with surfaces of endoluminal devices appear to be the initial step in a chain of events leading to tissue incorporation of the endovascular device.
- the present invention is based, in part, upon the relationship between surface energy of the material used to make the endoluminal device and protein adsorption at the surface of the endoluminal device.
- the present inventors have found that a relationship exists between surface free energy and protein adsorption on metals commonly used in fabrication of endoluminal devices.
- specific electrostatic forces resident on the surface of metal endoluminal stents have been found to influence blood interactions with the stent surface and the vascular wall.
- the inventive grafts, stent-grafts and web-stents have surface profiles which are achieved by fabricating the graft, stent-graft and web-stent by the same metal deposition methodologies as are used and standard in the microelectronic and nano-fabrication vacuum coating arts, and which are hereby incorporated by reference.
- the preferred deposition methodologies include ion-beam assisted evaporative deposition and sputtering techniques.
- ion beam-assisted evaporative deposition it is preferable to employ dual and simultaneous thermal electron beam evaporation with simultaneous ion bombardment of the material being deposited using an inert gas, such as argon, xenon, nitrogen or neon.
- an inert gas such as argon, xenon, nitrogen or neon.
- Bombardment with inert gas ions during deposition serves to reduce void content by increasing the atomic packing density in the deposited material.
- the reduced void content in the deposited material allows the mechanical properties of that deposited material to be similar to the bulk material properties. Deposition rates up to 20 nm/sec are achievable using ion beam-assisted evaporative deposition techniques.
- a 200-micron thick stainless steel film may be deposited within about four hours of deposition time.
- a cylindrical sputtering target a single circumferential source that concentrically surrounds the substrate that is held in a coaxial position within the source.
- Alternate deposition processes which may be employed to form the stent in accordance with the present invention are cathodic arc, laser ablation, and direct ion beam deposition.
- the crystalline structure of the deposited film affects the mechanical properties of the deposited film. These mechanical properties of the deposited film may be modified by post-process treatment, such as by, for example, annealing.
- Materials to make the inventive graft, stent-graft and web-stent are chosen for their biocompatibility, mechanical properties, i.e., tensile strength, yield strength, and their ease of deposition include, without limitation, the following: elemental titanium, vanadium, aluminum, nickel, tantalum, zirconium, chromium, silver, gold, silicon, magnesium, niobium, scandium, platinum, cobalt, palladium, manganese, molybdenum and alloys thereof, such as zirconium-titanium-tantalum alloys, nitinol, and stainless steel.
- the chamber pressure, the deposition pressure and the partial pressure of the process gases are controlled to optimize deposition of the desired species onto the substrate.
- the reactive and non-reactive gases are controlled and the inert or non- reactive gaseous species introduced into the deposition chamber are typically argon and nitrogen.
- the substrate may be either stationary or moveable; either rotated about its longitudinal axis, moved in an X-Y plane, planatarily or rotationally moved within the deposition chamber to facilitate deposition or patterning of the deposited material onto the substrate.
- the deposited material maybe deposited either as a uniform solid film onto the substrate, or patterned by (a) imparting either a positive or negative pattern onto the substrate, such as by etching or photolithography techniques applied to the substrate surface to create a positive or negative image of the desired pattern or (b) using a mask or set of masks which are either stationary or moveable relative to the substrate to define the pattern applied to the substrate. Patterning may be employed to achieve complex finished geometries of the resultant structural supports, web-regions or graft, both in the context of spatial orientation of patterns of regions of relative thickness and thinness, such as by varying the thickness of the film over its length to impart different mechanical characteristics under different delivery, deployment or in vivo environmental conditions.
- the device may be removed from the substrate after device formation by any of a variety of methods.
- the substrate may be removed by chemical means, such as etching or dissolution, by ablation, by machining or by ultrasonic energy.
- a sacrificial layer of a material such as carbon, aluminum or organic based materials, such as photoresists, may be deposited intermediate the substrate and the stent and the sacrificial layer removed by melting, chemical means, ablation, machining or other suitable means to free the stent from the substrate.
- the resulting device may then be subjected to post-deposition processing to modify the crystalline structure, such as by annealing, or to modify the surface topography, such as by etching to expose a heterogeneous surface of the device.
- the present invention therefore, consists of both a material and a process of making the inventive material.
- the inventive material is one for which mechanical strength and toughness is important, among other characteristics.
- the inventive material consists of several layers of 316L stainless steel, each of about 10 micrometers thick with no chemical differences between them. The layers are defined by interfaces between them that have an interface microroughness in excess of 2 nm rms. The cumulative thickness of the stainless steel film formed from this material is about 100 micrometers.
- the inventive material is preferably made by positioning a cylindrical copper mandrel along the axis of a cylindrical DC magnetron sputtering device.
- film deposition is carried out at a rate of 50 micrometers per hour for 12 minutes to obtain the first 10 micrometer thick layer.
- a negative bias voltage of 120 V is applied to the mandrel.
- the film grows and has a columnar structure in which columns reach though the whole thickness.
- the deposition process is interrupted for a brief period of time ( ⁇ 1 min). This time is sufficient for the formation of an adsorptive layer on the freshly deposited film.
- this adsorptive layer gives rise to columnar growth that that is different from the columnar growth of the previous layer only in that the columns are not continuous.
- the deposition process steps are then repeated until the desired cumulative material thickness is attained. At that point, the material, still on the mandrel, is removed from the vacuum deposition chamber and the copper mandrel is chemically removed. Additional post- deposition steps of surface finishing, cutting, etc. may be employed.
- FIGs 1 A and IB there is illustrated a multi-layered plied film in accordance with the present invention.
- the inventive film 10 consists of a plurality of individual layers 11 laminated upon one another to form the film 10.
- the individual layers may be made of the same biocompatible material, such as a biocompatible metal, or may be made of discrete biocompatible materials.
- the web-stent 20 is formed of a vacuum deposited laminated planar or cylindrical film 10.
- the web-stent 20 is formed by masking regions of the material blank which are to form a plurality of structural members 22, and then etching the unmasked regions which then form interstitial webs 24 which subtend interstitial regions between adjacent structural members 22.
- the interstitial webs 24 are etched to a material thickness that is less than the thickness of the plurality of structural members 22. It is preferable to impart a plurality of openings in the interstitial webs 24 in order to permit endothelialization of the luminal surface 26 of the interstitial webs 24.
- the openings may be imparted as a random pattern or as a regular pattern in the interstitial web 24, as will be discussed hereinafter.
- Stent-graft 30 is formed either from a tubular or planar laminated film 10, which is etched to form the plurality of structural members 32 and interstitial regions 34 between the structural members 32.
- a proximal 36 or a distal 38 graft region of the stent are provided and project outwardly from terminal structural members 32.
- the proximal graft region 36 and the distal graft region 38 are preferably etched to a reduced thickness of less than the thickness of the structural members, and are made with openings passing there through which promote cellular migration, as will be discussed hereinafter.
- the stent-graft 30 may be useful to employ with either or both of the proximal 36 or distal 38 graft regions projecting outwardly from the structural supports 32. Additionally, one or more of the plied individual layers 11 that comprise the laminate film 10 may project outwardly from the structural supports 32.
- An alternative embodiment of the invention is illustrated in Figures 4 and 5.
- the alternative embodiment of the stent-graft 30 involves covering the luminal and abluminal surfaces of a plurality of structural supports 32 with a luminal graft 36 and an abluminal graft 38.
- the luminal graft 36 may initially be formed as the proximal graft region 36 in Figure 3 and be luminally inverted 39 and passed into the lumen defined by the structural members 32.
- the abluminal graft 38 may initially be formed as the distal graft region 38 in Figure 3 and be abluminally everted 37 over the structural members 32.
- the luminal graft 36 and the abluminal graft 38 may be formed as either pre-fabricated discrete graft members made of biocompatible metal or metal-like materials that are either tubular or planar then formed into a tube and concentrically engaged about the plurality of structural members 32. Portions of each of the abluminal graft 38 and the luminal graft 36 are mechanically joined to the plurality of structural members 32 or to one and other, thereby effectively encapsulating the plurality of structural members 32 between the luminal graft 36 and the abluminal graft 38.
- each of the abluminal graft 38 and luminal graft 36 are mechanically joined to and co-terminus with a terminal portion of the plurality of structural members 32.
- Mechanical joining may be accomplished by methods such as welding, suturing, adhesive bonding, soldering, thermobonding, riveting, crimping, or dovetailing.
- the interstitial regions 34 may be subtended by a web 34, as discussed hereinabove, with reference to Figures 1 and 2.
- relatively thinner regions may be formed by removing bulk material by ion milling, laser ablation, EDM, laser machine, electron beam lithography, reactive ion etching, sputtering or equivalent methods which are capable of reducing the thickness of the material in either the graft region or the interstitial web region between the structural members.
- the structural members may be added to the defined interstitial web or graft regions to form the device, or the interstitial web or graft regions may be added to pre-existing structural members. Additive methods that may be employed include conventional metal forming techniques, including laminating, plating, or casting.
- initiafbulk material configurations including a substantially planar sheet substrate, an arcuate substrate or a tubular substrate, which is then processed by either subtractive or additive techniques discussed above.
- both the circumferential or hoop strength of the resultant device, as well as the longitudinal or columnar strength of the device are enhanced over conventional stent- graft devices.
- Additional advantages of the present invention, depending upon fabrication methods, may include: controlled homogeneity and/or heterogeneity of the material used to form the device by deposition methodologies, enhanced ability to control dimensional and mechanical characteristics of the device, the ability to fabricate complex device conformations, ability to pattern and control the porosity of the web and/or graft regions, and a monolithic one-piece construction of a device which yields a minimized device profile and cross-sectional area.
- the devices of the present invention have relatively thicker and thinner regions, in which the thinner regions permit radial collapse of the device for endoluminal delivery.
- the inventive device exhibits superior column strength that permits smaller introducer size and more readily facilitates deployment of the device.
- the web and/or graft regions, 44, 54 between adjacent structural members 42, 52 may be co-planar with either the luminal or abluminal surface of the structural members 42, or may be positioned intermediate the luminal 51 and abluminal 56 surfaces of the structural members 52.
- the web regions of the inventive web-stent, the graft regions of the inventive stent-graft and the inventive graft have a plurality of openings which pass through the thickness of the material used to fabricated the inventive devices.
- Each of the plurality of openings is dimensioned to permit cellular migration through the opening without permitting blood leakage or seepage through the plurality of openings.
- the plurality of openings may be random or may be patterned. However, in order to control the effective porosity of the device, it is desirable to impart a pattern of openings in the material used to fabricate the inventive device.
- Figures 8A-8C depict several examples of patterned openings in a section of material used to make the inventive web-stent, graft regions of the stent-graft, and the inventive graft.
- Figure 8A depicts a material 60 with a plurality of circular openings 64 passing through the material substrate 62.
- the plurality of circular openings is patterned in a regular array of rows and columns with regular inter-opening spacing 65 between adjacent openings.
- the diameter of each of the plurality of openings is about 19 ⁇ m, with an inter-opening spacing in each row and column of about 34 ⁇ m on center.
- the thickness of the material 62 is approximately 10 ⁇ m.
- Figure 8B illustrates another example of a pattern of a plurality of openings useful in the present invention.
- the material 62 which again is approximately 10 ⁇ m in thickness, has a plurality of openings 66 and 67 passing there through.
- the pattern of the plurality of openings 66 and 67 is an alternating slot pattern in which the plurality of openings 66 are arrayed adjacent one and other forming a y-axis oriented array 68 relative to the material 62, while a plurality of openings 67 are arrayed adjacent one and other forming an x-axis oriented array 69 relative to the material 62.
- the y- axis-oriented array 68 and the x-axis-oriented arcay 69 are then positioned adjacent one and other in the material 62.
- the inter-array spacing between the y- axis-oriented array 68 and the x-axis-oriented array 69 is about 17 ⁇ m, while each of the plurality of openings has a length of about 153 ⁇ m and a width of about 17 ⁇ m.
- Figure 8C illustrates a material 60 in which the material substrate 62 has a regular array of a plurality of diamond-shaped openings 63 passing through the material substrate 62.
- the dimension of the plurality of diamond-shaped openings 63 is of sufficient size to permit cellular migration through the openings 63, while preventing blood flow or seepage through the plurality of openings 63.
- FIGS 9A and 9B illustrate alternate preferred embodiments of the graft 70 and graft 80 in accordance with the present invention.
- Graft 70 consists generally of concentrically positioned luminal graft member 74 and abluminal graft member 72 and an interfacial region 74 where the luminal surface of the abluminal graft member 72 and the abluminal surface of the luminal graft member 74 are in immediate juxtaposition with one and other.
- Both the luminal 74 and the abluminal 72 graft members are fabricated in accordance with the methodologies described above, and are provided with a plurality of patterned openings 73 in the abluminal graft member 72 and a plurality of patterned openings 75 in the luminal graft member 74.
- the plurality of patterned openings 74 and 75 are positioned out of phase relative to one another. By positioning the plurality of patterned openings 74 and 75 in an out-of-phase relationship, there is no continuous opening that passes through the interracial . region 76 which would permit blood flow or seepage from the lumen of the graft. However, in order to permit cellular migration from the abluminal surface of the graft to the lumen of the graft, the interfacial region 76 should have microroughness [not shown] which is oriented either randomly or selectively, such as helically or circumferential, about the interfacial region 76.
- the microroughness preferably has a peak-to-valley depth of between about 5 ⁇ to about 65 ⁇ , most preferably between about lO ⁇ to 15 ⁇ , may be either on the luminal surface of the abluminal graft 72 or on the abluminal surface of the luminal graft 74, or both.
- the microroughness spans the surface area region between adjacent pairs of openings 74, 75, and the microroughness depth permits cellular migration across the surfaces between adjacent openings 74 and 75.
- the microroughness is not large enough to permit fluid passage through the inter-opening regions at the interface between the luminal graft 74 and the abluminal graft 72.
- This property of permitting cellular growth is similar to the difference between the porosity of expanded polytetrafluoroethylene grafts which do not require pre-clotting, and the much larger porosity of polyester or DACRON grafts which require pre-clotting to prevent fluid seepage there from.
- Figure 9B illustrates an alternative embodiment of the inventive graft 80 in which an abluminal graft member 82 is concentrically positioned about a luminal graft member 84.
- Each of the abluminal graft member 82 and the luminal graft member 84 having a plurality of patterned openings 83, 85, respectively, passing there through.
- the plurality of patterned openings 83 and 85 are positioned in an out- of-phase relationship to one and other in order to prevent forming a continuous opening between the luminal and abluminal surfaces of the graft 80.
- the annular open region 87 is created by providing a plurality of microprojections 86 that project either radially inward from the luminal surface of the abluminal graft member 82 or radially outward from the abluminal surface of the luminal graft member 84.
- the plurality of microprojections 86 act as spacers which abut the opposing surface of either the luminal graft member 84 or the abluminal graft member 82 which bound the annular open region 87.
- the height of the microprojections 86 and, therefore, the size of the annular open region 87 are dimensioned such that cells may migrate through the annular open region 87, while blood flow or seepage will not occur between the lumen and the abluminal surface of the graft 80.
- the size of the plurality of openings in the luminal graft member 74, 84 may be different than the size of the plurality of openings in the abluminal graft member 72, 82.
- the plurality of openings in the abluminal graft member 74, 84 preferably have a larger size than the plurality of openings in the luminal graft member 72, 84, while still retaining the out-of- phase relationship between the plurality of openings in the luminal 72, 82 and the abluminal 74, 84 graft members. Wliere circular openings are provided, it is preferable that the luminal 72, 82 and the abluminal 74, 84 graft members have openings having diameters of between about 5 ⁇ m and 100 ⁇ m.
- a third member may be interposed between the luminal 72, 82 and the abluminal 82, 84 graft members.
- the third member will preferably have a very fine plurality of openings, such as on the order of between 2-10 ⁇ , and permits use of a higher porosity in the luminal and abluminal grafts, without the need to maintain an out-of-phase relationship between the openings in the luminal 72, 82 and the abluminal 74, 84 graft members.
- the method 90 for fabricating the inventive grafts, stent-grafts and web-stents of the invention is illustrated in the process flow diagram in Figure 10.
- a starting blank of material by vacuum depositing a starting blank of a biocompatible metal or metal-like laminated film 94.
- the regions to remain are masked 98, then the unmasked regions are removed, such as by chemical etching or sputtering, to form the interstitial web regions, graft regions and/or openings in either the interstitial web regions and/or graft regions 99.
- Example 1 Stent Formation By Sputtering
- a ceramic cylindrical substrate is introduced into a deposition chamber with capabilities of glow discharge substrate cleaning and sputter deposition of carbon and stainless steel.
- the deposition chamber is evacuated to a pressure less than or equal to 2 x 10 " 7 Torr. Pre-cleaning of the substrate is conducted under vacuum by glow discharge.
- the substrate temperature is controlled to achieve a temperature between about 300 and 1100 degrees Centigrade.
- a bias voltage between -1000 and +1000 volts is applied to the substrate sufficient to cause energetic species arriving at the surface of the substrate to have hyperthermal energy between 0.1 eV and about 700 eV, preferably between 5-50 eV.
- The. deposition sources are circumferential and are oriented to deposit from the target circumferentially about the substrate.
- the deposition pressure is maintained between 0.1 and 10 mTorr.
- a sacrificial carbon layer of substantially uniform thickness ( ⁇ 5%) between 10 and 500 Angstroms is deposited circumferentially on the substrate.
- a cylindrical film of stainless steel is deposited onto the sacrificial carbon layer on the cylindrical substrate at a deposition rate between about 10 to 100 microns/hour.
- the substrate is removed from the deposition chamber and heated to volatilize the intermediate sacrificial carbon layer between the substrate and the film.
- the stainless steel film is removed from the substrate and exhibits material properties similar to the bulk stainless steel target and surface properties characterized by controlled heterogeneities in grain size, material composition and surface topography. A series of patterns are then machined into the resultant stainless steel film to form a stent by electrical discharge machining (EDM) or laser cutting the film.
- EDM electrical discharge machining
- Example 2 The same operating conditions are followed as in Example 1, except that the substrate is tubular and selected to have a coefficient of thermal expansion different than that of the resultant stent.
- No intermediate layer of sacrificial carbon is deposited onto the substrate, and the outer surface of the substrate is etched with a pattern of recesses defining a desired stent pattern.
- the substrate is mounted onto a rotational jig within the deposition chamber and rotated at a uniform rate during deposition. Tantalum is used as the target material and deposited into the recesses of the substrate from a single stationary source. After deposition, the temperature of the substrate and the deposited stent are controlled to impart diametric differential in the substrate and stent and permit removal of the stent from the substrate.
- Example 3 Stent Formation by Ion Beam-assisted Evaporative Deposition
- a cylindrical substrate is introduced into a deposition chamber that has capabilities of: substrate rotation and precise positioning, glow discharge substrate cleaning, ion beam- assisted evaporative deposition, and cylindrical magnetron sputtering.
- the deposition sources are (a) dual electron beam evaporative sources placed adjacent to one another at the base of the deposition chamber at a fixed distance from the substrate, these are used with simultaneous argon ion impingement onto the substrate from a controlled ion beam source, and (b) a cylindrical magnetron sputtering source with a carbon target capable of circumferentially coating a carbon sacrificial layer of substantially uniform thickness of between 10 and 200 Angstroms onto the substrate.
- the substrate temperature is controlled to achieve a substrate temperature between about 300 and 1100 degrees Centigrade.
- the deposition chamber is evacuated to a pressure less than or equal to 2 x 10 "7 Torr.
- a pre-cleaning of the substrate is conducted under vacuum by glow discharge.
- the substrate is rotated to ensure uniform cleaning and subsequent uniform deposition thickness.
- After cleaning the substrate is moved into the magnetron and coated with the carbon layer.
- the substrate is then moved into position to receive the stent-forming metal coating with simultaneous ion bombardment.
- One electron beam evaporation source contains titanium while the other source contains nickel.
- the evaporation rates of each of the titanium and nickel evaporation sources are separately controlled to form a nitinol alloy on the substrate as the stent-forming metal.
- the deposition source is a single electron beam evaporation source containing platinum and is used with simultaneous argon ion impingement onto the substrate from a controlled ion beam source.
- the substrate temperature is controlled to achieve a substrate temperature between about 300 and 1100 degrees Centigrade.
- the deposition chamber is evacuated to a pressure less than or equal to 2 x 10 "7 Torr. A pre-cleaning of the substrate is conducted under vacuum by glow discharge.
- the substrate After cleaning the substrate is moved into position within the deposition chamber and coated with platinum from the electron beam evaporation source with simultaneous argon ion bombardment, with the electron beam evaporation source passing platinum through a pattern mask corresponding to a stent pattern which is interposed between the source and the substrate to pass a pattern of platinum onto the substrate.
- the patterned stent is removed from the substrate and rolled about a forming substrate to a cylindrical shape and opposing ends of the planar stent material are brought into juxtaposition with one another and may be attached by laser welding or left uncoupled.
- Example 5 Thin-Film Deposition with Stent-Graft Etch The same conditions are employed as in Example 4, except that a unifonn layer of stent-forming material is deposited having a thickness of 150 microns without patterning of the stent onto the deposited layer. Rather, a negative mask is applied to the deposited stent- forming material, and a chemical etchant is introduced to etch a pattern of structural elements into the stent-forming metal. The etchant is permitted to react with the metal until a thinner film web having a thickness of between 2 -75 microns, is present between adjacent structural elements. After the thinner film web is formed, the etching is. stopped, and the resultant stent-graft is removed and formed into a tubular shape.
- Example 6 Dry Etching Method The same conditions as in Example 5 are followed, except that reactive ion etching is employed to form the thinner film web.
- Example 5 The same conditions are followed as in Example 5, except that the structural elements are defined in an intermediate region of a tubular substrate, and interstitial regions between adjacent structural elements are etched by chemical etching until interstitial openings are formed between adjacent structural elements while masking the structural elements and proximal and distal regions of the tubular substrate. Proximal and distal graft regions are formed adjacent the intermediate region of the tubular substrate and contiguous with the plurality of structural elements, by masking the structural elements and interstitial openings and chemical etching the proximal and distal regions of the tubular substrate to yield a thinner film of material in the proximal and distal regions of the tubular substrate.
- proximal and distal graft regions are then everted, with the proximal graft region being inverted luminally through the lumen of the structural members and the distal graft region being everted abluminally over the structural members.
- the proximal graft region is mechanically joined to the distal terminal end of the plurality of structural members, while the distal graft region is mechanically joined to the proximal terminal end of the plurality of structural members, thereby encapsulating the plurality of structural members between the everted proximal and distal graft regions.
- Example 8 Stent-Graft Formation - Discrete Graft and Discrete Stent
- a pre-fabricated self-expanding superelastic shape memory alloy stent is provided.
- Two cylindrical hypotubes of a superelastic shape memory material similar to that of the stent are chemically etched to a substantially uniform thickness of 10 ⁇ m, with a first hypotube having an inner diameter which is of sufficient size to accommodate the outer diameter of the stent, and a second hypotube having an outer diameter dimensioned to accommodate the inner diameter of the stent.
- the etched hypotubes are then placed into a vacuum chamber and a cylindrical pattern mask having a regular array of circular openings, each circular opening having a diameter of about 25 ⁇ m, is positioned concentrically about each of the cylindrical hypotubes.
- the etched hypotubes are reactive ion etched to transfer the masked pattern to the etched hypotube and impart a pattern of circular openings that pass through the wall thickness of the etched hypotubes corresponding to the mask pattern.
- the stent, and first and second etched and reactive ion etched hypotubes are concentrically engaged upon one and other, with the second hypotube being concentrically positioned within the lumen of the stent and the first hypotube being concentrically positioned about the abluminal surface of the stent.
- Proximal and distal ends of the stent, the first hypotube and the second hypotube are mechanically joined by welding and then trimmed by laser cutting to ensure that the proximal and distal ends are co-terminus.
- a cylindrical mandrel is provided which is coated with a sacrificial layer.
- a plurality of patterned recesses is defined in the sacrificial layer.
- the mandrel is introduced into a deposition chamber and a nickel-titanium alloy is vacuum deposited onto the mandrel, while rotating the mandrel, until a uniform adherent layer of the deposited nickel-titanium alloy covers the cylindrical mandrel.
- the sacrificial layer is removed, and the uniform adherent layer disengaged from the cylindrical mandrel, yielding the inventive graft, with openings corresponding to the plurality of patterned recesses in the graft material.
- Example 10 Planar Laminated Film
- a vacuum chamber capable of being pumped to 5 x 10 -7 Torr is provided with and installed within industry standard thin-film deposition equipment described as follows.
- An electron beam gun capable of evaporating metals is placed at the base of the chamber.
- the gun crucible is filled with a charge of high purity aluminum.
- a film thickness and deposition rate control and monitoring device is installed above and to the side of the gun, capable of monitoring and controlling incident .power to the gun crucible in order to control deposition rate.
- a fixture to hold a planar substrate is installed fifty cm above and centered over the gun.
- a moveable shutter is placed between the gun and the substrate fixture, such that at a given and appropriate time the shutter can be removed from the deposition path to allow deposition onto a substrate.
- Infrared heaters are installed in the chamber in a position that allows controlled heating of the substrate to 200 degrees C.
- An ion beam gun is installed in the chamber in such a position that a formed and controlled Ar ion beam can be directed onto a substrate held in the substrate fixture.
- the following steps are taken to form a laminate / multilayer film on a substrate.
- a section of 316L stainless steel sheet metal, 36" square and .016" thick is attached to the substrate holding fixture to serve as the deposition substrate.
- the chamber is pumped to a base pressure of 5 x 10 ⁇ 7 Torr.
- the infrared heaters are engaged to heat and maintain the substrate at 200 degrees C.
- the electron beam gun power is ramped up which heats and outgases the aluminum charge.
- the aluminum charge is heated to obtain a vapor pressure compatible with a deposition rate equivalent to 75 angstroms per second.
- the ion beam gun is started and a stable 200 volt Ar ion beam with the current density of 0.5 mA/cm 2 is formed, at a chamber pressure of 3 x 10 -5 Torr.
- the shutter is opened.
- An aluminum film of 5000 angstroms thickness is deposited onto the substrate. At this point the shutter is closed and the electron beam gun power is reduced to zero.
- the ion beam gun remains running.
- the chamber is backfilled with oxygen to a pressure of 8 x 10 -4 Torr.
- the shutter reopens allowing Ar ion impingement of the substrate in the oxygen environment for three minutes. At this point the shutter is closed and the oxygen flow is ceased.
- the chamber is allowed to pump back down to 3 x 10 -5 Torr.
- the electron beam gun is restarted, which again outgases the aluminum charge and brings it to the appropriate deposition vapor pressure.
- the shutter reopens and a second aluminum layer of 5000 angstrom thickness is deposited onto the substrate. Again the shutter is closed and the electron beam gun power reduced to zero. This layer is then Ar ion impinged in an oxygen backfilled environment as before. This cycle is repeated to form multiple successive layers as are required for form a multilayer film of 50 micron total thickness.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001583835A JP2004512059A (en) | 2000-05-12 | 2001-05-11 | Self-supported laminated film structure material, medical device manufactured from the same, and method of manufacturing the same |
EP01935352A EP1280565A2 (en) | 2000-05-12 | 2001-05-11 | Self-supporting laminated films, structural materials and medical devices |
AU2001261455A AU2001261455B2 (en) | 2000-05-12 | 2001-05-11 | Self-supporting laminated films, structural materials and medical devices |
AU6145501A AU6145501A (en) | 2000-05-12 | 2001-05-11 | Self-supporting laminated films, structural materials and medical devices manufactured therefrom and methods of making same |
CA002408801A CA2408801A1 (en) | 2000-05-12 | 2001-05-11 | Self-supporting laminated films, structural materials and medical devices |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20383500P | 2000-05-12 | 2000-05-12 | |
US60/203,835 | 2000-05-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001087371A2 true WO2001087371A2 (en) | 2001-11-22 |
WO2001087371A3 WO2001087371A3 (en) | 2002-03-07 |
Family
ID=22755522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/015284 WO2001087371A2 (en) | 2000-05-12 | 2001-05-11 | Self-supporting laminated films, structural materials and medical devices |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1280565A2 (en) |
JP (1) | JP2004512059A (en) |
AU (2) | AU2001261455B2 (en) |
CA (1) | CA2408801A1 (en) |
WO (1) | WO2001087371A2 (en) |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004002369A1 (en) * | 2002-06-27 | 2004-01-08 | Boston Scientific Limited | Methods of making endoprostheses |
JP2006505307A (en) * | 2002-09-26 | 2006-02-16 | アドヴァンスド バイオ プロスセティック サーフェシーズ リミテッド | Implantable material with designed surface and method of making the material |
WO2007033320A1 (en) * | 2005-09-14 | 2007-03-22 | Boston Scientific Limited | Method of processing a stent |
JP2007518528A (en) * | 2004-01-22 | 2007-07-12 | イソフラックス・インコーポレイテッド | Radiopaque coatings for biomedical devices |
WO2008000467A1 (en) * | 2006-06-27 | 2008-01-03 | Acandis Gmbh & Co. Kg | A method for the production of structured layers of titanium and nickel |
JP2008502425A (en) * | 2004-06-14 | 2008-01-31 | イソフラックス・インコーポレイテッド | Radiopaque coatings for biomedical devices |
DE102006039840A1 (en) * | 2006-08-25 | 2008-03-20 | Acandis Gmbh & Co. Kg | Thrombosis filter with cover layer |
WO2007093423A3 (en) * | 2006-02-15 | 2008-05-29 | Acandis Gmbh & Co Kg | Method for coating a stent |
WO2010136215A1 (en) * | 2009-05-29 | 2010-12-02 | Acandis Gmbh & Co. Kg | Method for producing a medical functional element comprising a self-supporting lattice structure |
CN102198025A (en) * | 2011-05-04 | 2011-09-28 | 迟立群 | Stent graft |
US8268340B2 (en) | 2002-09-26 | 2012-09-18 | Advanced Bio Prosthetic Surfaces, Ltd. | Implantable materials having engineered surfaces and method of making same |
US8529616B2 (en) | 2002-11-25 | 2013-09-10 | Advanced Bio Prosthetic Surfaces, Ltd., a wholly owned subsidary of Palmaz Scientific, Inc. | Implantable expandable medical devices having regions of differential mechanical properties and methods of making same |
US8632583B2 (en) | 2011-05-09 | 2014-01-21 | Palmaz Scientific, Inc. | Implantable medical device having enhanced endothelial migration features and methods of making the same |
EP2707044A2 (en) * | 2011-05-13 | 2014-03-19 | Palmaz Scientific, Inc. | Implantable materials having engineered surfaces and method of making same |
US8728563B2 (en) | 2011-05-03 | 2014-05-20 | Palmaz Scientific, Inc. | Endoluminal implantable surfaces, stents, and grafts and method of making same |
US8894824B2 (en) | 2004-06-28 | 2014-11-25 | Isoflux, Inc. | Porous coatings for biomedical implants |
US8910363B2 (en) | 1999-11-19 | 2014-12-16 | Advanced Bio Prosthetic Surfaces, Ltd. | Compliant implantable medical devices and methods of making same |
US9486431B2 (en) | 2008-07-17 | 2016-11-08 | Micell Technologies, Inc. | Drug delivery medical device |
US9486338B2 (en) | 2007-04-17 | 2016-11-08 | Micell Technologies, Inc. | Stents having controlled elution |
US9687864B2 (en) | 2010-03-26 | 2017-06-27 | Battelle Memorial Institute | System and method for enhanced electrostatic deposition and surface coatings |
US9737645B2 (en) | 2006-04-26 | 2017-08-22 | Micell Technologies, Inc. | Coatings containing multiple drugs |
US9737642B2 (en) | 2007-01-08 | 2017-08-22 | Micell Technologies, Inc. | Stents having biodegradable layers |
US9789233B2 (en) | 2008-04-17 | 2017-10-17 | Micell Technologies, Inc. | Stents having bioabsorbable layers |
US9827117B2 (en) | 2005-07-15 | 2017-11-28 | Micell Technologies, Inc. | Polymer coatings containing drug powder of controlled morphology |
US9981072B2 (en) | 2009-04-01 | 2018-05-29 | Micell Technologies, Inc. | Coated stents |
US10117972B2 (en) | 2011-07-15 | 2018-11-06 | Micell Technologies, Inc. | Drug delivery medical device |
US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
US10232092B2 (en) | 2010-04-22 | 2019-03-19 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
US10272606B2 (en) | 2013-05-15 | 2019-04-30 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
US10350391B2 (en) | 2008-07-17 | 2019-07-16 | Micell Technologies, Inc. | Drug delivery medical device |
US10464100B2 (en) | 2011-05-31 | 2019-11-05 | Micell Technologies, Inc. | System and process for formation of a time-released, drug-eluting transferable coating |
US10835396B2 (en) | 2005-07-15 | 2020-11-17 | Micell Technologies, Inc. | Stent with polymer coating containing amorphous rapamycin |
US11039943B2 (en) | 2013-03-12 | 2021-06-22 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
US11369498B2 (en) | 2010-02-02 | 2022-06-28 | MT Acquisition Holdings LLC | Stent and stent delivery system with improved deliverability |
US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
US11904118B2 (en) | 2010-07-16 | 2024-02-20 | Micell Medtech Inc. | Drug delivery medical device |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7736687B2 (en) | 2006-01-31 | 2010-06-15 | Advance Bio Prosthetic Surfaces, Ltd. | Methods of making medical devices |
US7335426B2 (en) | 1999-11-19 | 2008-02-26 | Advanced Bio Prosthetic Surfaces, Ltd. | High strength vacuum deposited nitinol alloy films and method of making same |
WO2004028340A2 (en) | 2002-09-26 | 2004-04-08 | Advanced Bio Prosthetic Surfaces, Ltd. | High strength vacuum deposited nitionol alloy films, medical thin film graft materials and method of making same |
US7901447B2 (en) | 2004-12-29 | 2011-03-08 | Boston Scientific Scimed, Inc. | Medical devices including a metallic film and at least one filament |
US8992592B2 (en) | 2004-12-29 | 2015-03-31 | Boston Scientific Scimed, Inc. | Medical devices including metallic films |
US8998973B2 (en) | 2004-03-02 | 2015-04-07 | Boston Scientific Scimed, Inc. | Medical devices including metallic films |
US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
WO2008052000A2 (en) | 2006-10-23 | 2008-05-02 | Micell Technologies, Inc. | Holder for electrically charging a substrate during coating |
WO2008148013A1 (en) | 2007-05-25 | 2008-12-04 | Micell Technologies, Inc. | Polymer films for medical device coating |
US8834913B2 (en) | 2008-12-26 | 2014-09-16 | Battelle Memorial Institute | Medical implants and methods of making medical implants |
US10040313B2 (en) * | 2013-10-04 | 2018-08-07 | The Procter & Gamble Company | Processes and machines for decorating articles of manufacture |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5387247A (en) * | 1983-10-25 | 1995-02-07 | Sorin Biomedia S.P.A. | Prosthetic device having a biocompatible carbon film thereon and a method of and apparatus for forming such device |
US5607463A (en) * | 1993-03-30 | 1997-03-04 | Medtronic, Inc. | Intravascular medical device |
US5649951A (en) * | 1989-07-25 | 1997-07-22 | Smith & Nephew Richards, Inc. | Zirconium oxide and zirconium nitride coated stents |
US5725573A (en) * | 1994-03-29 | 1998-03-10 | Southwest Research Institute | Medical implants made of metal alloys bearing cohesive diamond like carbon coatings |
US5891507A (en) * | 1997-07-28 | 1999-04-06 | Iowa-India Investments Company Limited | Process for coating a surface of a metallic stent |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5723004A (en) * | 1993-10-21 | 1998-03-03 | Corvita Corporation | Expandable supportive endoluminal grafts |
US6287249B1 (en) * | 1998-02-19 | 2001-09-11 | Radiance Medical Systems, Inc. | Thin film radiation source |
US6096175A (en) * | 1998-07-17 | 2000-08-01 | Micro Therapeutics, Inc. | Thin film stent |
-
2001
- 2001-05-11 AU AU2001261455A patent/AU2001261455B2/en not_active Expired
- 2001-05-11 AU AU6145501A patent/AU6145501A/en active Pending
- 2001-05-11 EP EP01935352A patent/EP1280565A2/en not_active Ceased
- 2001-05-11 CA CA002408801A patent/CA2408801A1/en not_active Abandoned
- 2001-05-11 JP JP2001583835A patent/JP2004512059A/en active Pending
- 2001-05-11 WO PCT/US2001/015284 patent/WO2001087371A2/en active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5387247A (en) * | 1983-10-25 | 1995-02-07 | Sorin Biomedia S.P.A. | Prosthetic device having a biocompatible carbon film thereon and a method of and apparatus for forming such device |
US5649951A (en) * | 1989-07-25 | 1997-07-22 | Smith & Nephew Richards, Inc. | Zirconium oxide and zirconium nitride coated stents |
US5607463A (en) * | 1993-03-30 | 1997-03-04 | Medtronic, Inc. | Intravascular medical device |
US5725573A (en) * | 1994-03-29 | 1998-03-10 | Southwest Research Institute | Medical implants made of metal alloys bearing cohesive diamond like carbon coatings |
US5891507A (en) * | 1997-07-28 | 1999-04-06 | Iowa-India Investments Company Limited | Process for coating a surface of a metallic stent |
Non-Patent Citations (1)
Title |
---|
See also references of EP1280565A2 * |
Cited By (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8910363B2 (en) | 1999-11-19 | 2014-12-16 | Advanced Bio Prosthetic Surfaces, Ltd. | Compliant implantable medical devices and methods of making same |
US10745799B2 (en) | 1999-11-19 | 2020-08-18 | Vactronix Scientific, Llc | Compliant implantable medical devices and methods of making same |
US10106884B2 (en) | 1999-11-19 | 2018-10-23 | Vactronix Scientific, Llc | Compliant implantable medical devices and methods of making same |
US6865810B2 (en) | 2002-06-27 | 2005-03-15 | Scimed Life Systems, Inc. | Methods of making medical devices |
WO2004002369A1 (en) * | 2002-06-27 | 2004-01-08 | Boston Scientific Limited | Methods of making endoprostheses |
US8932347B2 (en) | 2002-09-26 | 2015-01-13 | Advanced Bio Prosthetic Surfaces, Ltd. | Implantable materials having engineered surfaces and method of making same |
US8268340B2 (en) | 2002-09-26 | 2012-09-18 | Advanced Bio Prosthetic Surfaces, Ltd. | Implantable materials having engineered surfaces and method of making same |
US10039866B2 (en) | 2002-09-26 | 2018-08-07 | Vactronix Scientific, Llc | Implantable materials having engineered surfaces and method of making same |
US9272077B2 (en) | 2002-09-26 | 2016-03-01 | Palmaz Scientific, Inc. | Implantable materials having engineered surfaces and method of making same |
JP2006505307A (en) * | 2002-09-26 | 2006-02-16 | アドヴァンスド バイオ プロスセティック サーフェシーズ リミテッド | Implantable material with designed surface and method of making the material |
US10729824B2 (en) | 2002-09-26 | 2020-08-04 | Vactronix Scientific, Llc. | Implantable materials having engineered surfaces and method of making same |
US10034967B2 (en) | 2002-09-26 | 2018-07-31 | Vactronix Scientific, Llc | Implantable biomaterials having engineered functional surfaces |
US10314949B2 (en) | 2002-09-26 | 2019-06-11 | Vactronix Scientific, Llc | Implantable biomaterials having functional surfaces |
US8679517B2 (en) | 2002-09-26 | 2014-03-25 | Palmaz Scientific, Inc. | Implantable materials having engineered surfaces made by vacuum deposition and method of making same |
US8147859B2 (en) | 2002-09-26 | 2012-04-03 | Advanced Bio Prosthetic Surfaces, Ltd. | Implantable material having patterned surface of raised elements and photochemically altered elements and method of making same |
US8709066B2 (en) | 2002-09-26 | 2014-04-29 | Advanced Bio Prosthetic Surfaces, Ltd. | Implantable materials having engineered surfaces comprising a pattern of features and method of making same |
US10682443B2 (en) | 2002-09-26 | 2020-06-16 | Vactronix Scientific, Llc | Implantable biomaterials having functional surfaces |
US9532890B2 (en) | 2002-11-25 | 2017-01-03 | Vactronix Scientific, Inc. | Implantable expandable medical devices having regions of differential mechanical properties and methods of making same |
US8529616B2 (en) | 2002-11-25 | 2013-09-10 | Advanced Bio Prosthetic Surfaces, Ltd., a wholly owned subsidary of Palmaz Scientific, Inc. | Implantable expandable medical devices having regions of differential mechanical properties and methods of making same |
US11045338B2 (en) | 2002-11-25 | 2021-06-29 | Vactronix Scientific | Implantable expandable medical devices having regions of differential mechanical properties and methods of making same |
US8002822B2 (en) | 2004-01-22 | 2011-08-23 | Isoflux, Inc. | Radiopaque coating for biomedical devices |
JP2007518528A (en) * | 2004-01-22 | 2007-07-12 | イソフラックス・インコーポレイテッド | Radiopaque coatings for biomedical devices |
JP2008502425A (en) * | 2004-06-14 | 2008-01-31 | イソフラックス・インコーポレイテッド | Radiopaque coatings for biomedical devices |
US8894824B2 (en) | 2004-06-28 | 2014-11-25 | Isoflux, Inc. | Porous coatings for biomedical implants |
US10835396B2 (en) | 2005-07-15 | 2020-11-17 | Micell Technologies, Inc. | Stent with polymer coating containing amorphous rapamycin |
US10898353B2 (en) | 2005-07-15 | 2021-01-26 | Micell Technologies, Inc. | Polymer coatings containing drug powder of controlled morphology |
US11911301B2 (en) | 2005-07-15 | 2024-02-27 | Micell Medtech Inc. | Polymer coatings containing drug powder of controlled morphology |
US9827117B2 (en) | 2005-07-15 | 2017-11-28 | Micell Technologies, Inc. | Polymer coatings containing drug powder of controlled morphology |
US7647687B2 (en) | 2005-09-14 | 2010-01-19 | Boston Scientific Scimed, Inc. | Method of manufacturing a stent |
WO2007033320A1 (en) * | 2005-09-14 | 2007-03-22 | Boston Scientific Limited | Method of processing a stent |
WO2007093423A3 (en) * | 2006-02-15 | 2008-05-29 | Acandis Gmbh & Co Kg | Method for coating a stent |
US9737645B2 (en) | 2006-04-26 | 2017-08-22 | Micell Technologies, Inc. | Coatings containing multiple drugs |
US11007307B2 (en) | 2006-04-26 | 2021-05-18 | Micell Technologies, Inc. | Coatings containing multiple drugs |
US11850333B2 (en) | 2006-04-26 | 2023-12-26 | Micell Medtech Inc. | Coatings containing multiple drugs |
US8338311B2 (en) | 2006-06-27 | 2012-12-25 | Acandis Gmbh & Co. Kg | Method for the production of structured layers of titanium and nickel |
WO2008000467A1 (en) * | 2006-06-27 | 2008-01-03 | Acandis Gmbh & Co. Kg | A method for the production of structured layers of titanium and nickel |
WO2008022799A3 (en) * | 2006-08-25 | 2009-03-12 | Acandis Gmbh & Co Kg | Thrombosis filter with cover layer |
US8308928B2 (en) | 2006-08-25 | 2012-11-13 | Acandis Gmbh & Co. Kg | Thrombosis filter with cover layer |
DE102006039840A1 (en) * | 2006-08-25 | 2008-03-20 | Acandis Gmbh & Co. Kg | Thrombosis filter with cover layer |
US9737642B2 (en) | 2007-01-08 | 2017-08-22 | Micell Technologies, Inc. | Stents having biodegradable layers |
US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
US10617795B2 (en) | 2007-01-08 | 2020-04-14 | Micell Technologies, Inc. | Stents having biodegradable layers |
US9486338B2 (en) | 2007-04-17 | 2016-11-08 | Micell Technologies, Inc. | Stents having controlled elution |
US9775729B2 (en) | 2007-04-17 | 2017-10-03 | Micell Technologies, Inc. | Stents having controlled elution |
US10350333B2 (en) | 2008-04-17 | 2019-07-16 | Micell Technologies, Inc. | Stents having bioabsorable layers |
US9789233B2 (en) | 2008-04-17 | 2017-10-17 | Micell Technologies, Inc. | Stents having bioabsorbable layers |
US9981071B2 (en) | 2008-07-17 | 2018-05-29 | Micell Technologies, Inc. | Drug delivery medical device |
US9486431B2 (en) | 2008-07-17 | 2016-11-08 | Micell Technologies, Inc. | Drug delivery medical device |
US10350391B2 (en) | 2008-07-17 | 2019-07-16 | Micell Technologies, Inc. | Drug delivery medical device |
US10653820B2 (en) | 2009-04-01 | 2020-05-19 | Micell Technologies, Inc. | Coated stents |
US9981072B2 (en) | 2009-04-01 | 2018-05-29 | Micell Technologies, Inc. | Coated stents |
US8758636B2 (en) | 2009-05-29 | 2014-06-24 | Acandis Gmbh & Co. Kg | Method for producing a medical functional element comprising a selfsupporting lattice structure |
WO2010136215A1 (en) * | 2009-05-29 | 2010-12-02 | Acandis Gmbh & Co. Kg | Method for producing a medical functional element comprising a self-supporting lattice structure |
US11369498B2 (en) | 2010-02-02 | 2022-06-28 | MT Acquisition Holdings LLC | Stent and stent delivery system with improved deliverability |
US9687864B2 (en) | 2010-03-26 | 2017-06-27 | Battelle Memorial Institute | System and method for enhanced electrostatic deposition and surface coatings |
US10232092B2 (en) | 2010-04-22 | 2019-03-19 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
US11904118B2 (en) | 2010-07-16 | 2024-02-20 | Micell Medtech Inc. | Drug delivery medical device |
US8728563B2 (en) | 2011-05-03 | 2014-05-20 | Palmaz Scientific, Inc. | Endoluminal implantable surfaces, stents, and grafts and method of making same |
CN102198025A (en) * | 2011-05-04 | 2011-09-28 | 迟立群 | Stent graft |
US10206772B2 (en) | 2011-05-09 | 2019-02-19 | Vactronix Scientific, Llc | Implantable medical device having enhanced endothelial migration features and methods of making the same |
US8632583B2 (en) | 2011-05-09 | 2014-01-21 | Palmaz Scientific, Inc. | Implantable medical device having enhanced endothelial migration features and methods of making the same |
US10786343B2 (en) | 2011-05-09 | 2020-09-29 | Vactronix Scientific, Llc | Implantable medical device having enhanced endothelial migration features and methods of making the same |
EP2707044A4 (en) * | 2011-05-13 | 2014-10-29 | Palmaz Scient Inc | Implantable materials having engineered surfaces and method of making same |
EP2707044A2 (en) * | 2011-05-13 | 2014-03-19 | Palmaz Scientific, Inc. | Implantable materials having engineered surfaces and method of making same |
AU2012255972B2 (en) * | 2011-05-13 | 2016-06-23 | Vactronix Scientific, Llc | Implantable materials having engineered surfaces and method of making same |
US10464100B2 (en) | 2011-05-31 | 2019-11-05 | Micell Technologies, Inc. | System and process for formation of a time-released, drug-eluting transferable coating |
US10729819B2 (en) | 2011-07-15 | 2020-08-04 | Micell Technologies, Inc. | Drug delivery medical device |
US10117972B2 (en) | 2011-07-15 | 2018-11-06 | Micell Technologies, Inc. | Drug delivery medical device |
US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
US11039943B2 (en) | 2013-03-12 | 2021-06-22 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
US10272606B2 (en) | 2013-05-15 | 2019-04-30 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
Also Published As
Publication number | Publication date |
---|---|
EP1280565A2 (en) | 2003-02-05 |
JP2004512059A (en) | 2004-04-22 |
CA2408801A1 (en) | 2001-11-22 |
AU2001261455B2 (en) | 2007-01-25 |
AU6145501A (en) | 2001-11-26 |
WO2001087371A3 (en) | 2002-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10945828B2 (en) | Self-supporting laminated films, structural materials and medical devices manufactured therefrom and methods of making same | |
US6849085B2 (en) | Self-supporting laminated films, structural materials and medical devices manufactured therefrom and method of making same | |
AU2001261455B2 (en) | Self-supporting laminated films, structural materials and medical devices | |
US10363125B2 (en) | Method of making implantable medical devices having controlled surface properties | |
AU2001261455A1 (en) | Self-supporting laminated films, structural materials and medical devices | |
CA2390942C (en) | Endoluminal device exhibiting improved endothelialization and method of manufacture thereof | |
AU2001245884A1 (en) | Endoluminal implantable devices and method of making same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2408801 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001935352 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001261455 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2001935352 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001261455 Country of ref document: AU |